BASEL, SWITZERLAND--(Marketwire - November 06, 2012) - Basilea Pharmaceutica AG /
Basilea's novel oncology drug candidate BAL101553: data presented at
international conference demonstrate dual mode of action. Processed and
transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Basilea Pharmaceutica Ltd. (SIX: BSLN)
reported today that new research data on its innovative anti-cancer drug
BAL101553 are being presented at the 24(th) Symposium on "Molecular Targets
Cancer Therapeutics" taking place in Dublin, Ireland, from November 6 to
9, 2012, hosted by the European Organisation for Research and Treatment of
Cancer (EORTC), the U.S. National Cancer Institute (NCI) and the American
Association for Cancer Research (AACR).
BAL101553, a highly soluble prodrug of Basilea's BAL27862, is a novel small
molecule agent targeting microtubules, the intracellular structural network
essential for cell division. BAL27862 has demonstrated broad anti-cancer
activity in preclinical models of human cancer resistant to conventional
microtubule-targeting drugs such as taxanes or vinca alkaloids. BAL101553
potential for both intravenous and oral administration. The injectable form
currently being tested in a phase I study in patients with advanced solid
BAL101553 has a dual mechanism of action (poster/abstract #421) with direct
activity against drug-resistant cancer cells and a pronounced effect on
eliminating tumor blood supply. In animal models, short-term treatment of
led to a dramatic reduction in tumor cell growth and viability, associated
almost complete eradication of functional tumor blood vessels. Importantly,
blood vessel function in normal tissue was not affected. Vascular
activity was also shown in an in vitro model that mimics capillary
Further data supporting the unique anti-cancer profile and mode of action
this novel agent were generated in collaboration with the group of Diane
of the Aix-Marseille University, France. Details of distinct effects on
microtubule biology are presented (poster/abstract #422). These show that
BAL27862 blocks tumor cell division by altering microtubule dynamics in a
way as compared to conventional microtubule-targeting agents.
Dr. Laurenz Kellenberger, Basilea's Chief Scientific Officer, commented:
"Resistance against established drugs is a major challenge in cancer
necessitates the development of new oncology drugs with novel mechanisms of
action to overcome such resistance. The dual mode of action of BAL101553,
attacking tumor cells that are resistant to other agents as well as
blood vessels of the tumor underlines its promising profile as a potential
agent for the treatment of refractory human cancers."
|Posters on BAL101553/BAL27862 |
|to be presented in poster session "Tubulin-Interacting Agents"|
|on November 8, 2012 |
|Dual mechanism of action of the novel microtubule-targeting |
|drug BAL27862 (active moiety of the prodrug BAL101553): |
|targeting tumor and vascular cells - F. Bachmann, H.A. Lane; |
|poster #421 |
|Antitumor activity of BAL27862 (active moiety of the prodrug |
|BAL101553) is associated with the generation of short |
|non-centrosomal microtubules - A. Rovini, S. Honoré, N. |
|McKay, F. Bachmann, H.A. Lane, D. Braguer; poster #422 |
For further information please visit www.ecco-org.eu/ENA.
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and
the SIX Swiss Exchange (SIX: BSLN). Through the fully integrated research
development operations of its Swiss subsidiary Basilea Pharmaceutica
International Ltd. ("Basilea") the company focuses on innovative
products in the therapeutic areas of bacterial infections, fungal
oncology, targeting the medical challenge of rising resistance and
to current treatment options.
This communication expressly or implicitly contains certain
statements concerning Basilea Pharmaceutica Ltd. and its business. Such
statements involve certain known and unknown risks, uncertainties and other
factors, which could cause the actual results, financial condition,
or achievements of Basilea Pharmaceutica Ltd. to be materially different
any future results, performance or achievements expressed or implied by
forward-looking statements. Basilea Pharmaceutica Ltd. is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new information,
events or otherwise.
This press release can be downloaded from www.basilea.com.
Press release (PDF):
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Basilea Pharmaceutica AG via Thomson Reuters ONE